Compile Data Set for Download or QSAR
Report error Found 212 Enz. Inhib. hit(s) with all data for entry = 8886
TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426423(US10526336, Example 42 | 1-(2-((2R,5R)-5-((3- (dif...)
Affinity DataIC50: 5nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426469(US10526336, Example 88 | (2-(2H-1,2,3-triazol-2-yl...)
Affinity DataIC50: 7.30nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426387(US10526336, Example 6 | US10526336, Example 11 | (...)
Affinity DataIC50: 8nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426414(US10526336, Example 33 | US10526336, Example 41 | ...)
Affinity DataIC50: 8.90nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426407(US10526336, Example 26 | (2-(2H-1,2,3-triazol-2-yl...)
Affinity DataIC50: 9.10nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426409(US10526336, Example 28 | 1-(2-((2R,5R)-5-((3- chlo...)
Affinity DataIC50: 9.5nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426425(US10526336, Example 44 | (2-(2H-tetrazol-2-yl)phen...)
Affinity DataIC50: 9.60nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426451(US10526336, Example 70 | (2-(2H-1,2,3-triazol-2-yl...)
Affinity DataIC50: 9.80nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426386(US10526336, Example 5 | (2-(2H-1,2,3-triazol-2-yl)...)
Affinity DataIC50: 10.3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426421(US10526336, Example 40 | (2-(2H-1,2,3-triazol-2-yl...)
Affinity DataIC50: 10.5nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426407(US10526336, Example 26 | (2-(2H-1,2,3-triazol-2-yl...)
Affinity DataIC50: 12.1nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426413(US10526336, Example 32 | (2-(2H-1,2,3-triazol-2-yl...)
Affinity DataIC50: 12.6nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426440(US10526336, Example 59 | 1-(2-((2R,5R)-2-methyl-5-...)
Affinity DataIC50: 12.8nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426414(US10526336, Example 33 | US10526336, Example 41 | ...)
Affinity DataIC50: 13.1nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426390(US10526336, Example 9 | 1-(2-((2R,5R)-2-methyl-5-(...)
Affinity DataIC50: 13.2nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426411(US10526336, Example 30 | (2-(2H-1,2,3-triazol-2-yl...)
Affinity DataIC50: 13.9nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426454(US10526336, Example 73 | (4-fluoro-2-(2H-1,2,3-tri...)
Affinity DataIC50: 14nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426487(US10526336, Example 102 | (2-(2H-1,2,3-triazol-2-y...)
Affinity DataIC50: 14nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426453(US10526336, Example 72 | 1-(2-((2R,5R)-2-methyl-5-...)
Affinity DataIC50: 14.3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426410(US10526336, Example 29 | (2-(2H-1,2,3-triazol-2- y...)
Affinity DataIC50: 14.3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426447(US10526336, Example 66 | ((2R,5R)-2-methyl-5-((3-(...)
Affinity DataIC50: 14.9nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426466(US10526336, Example 85 | ((2R,5R)-2-methyl-5-(pyra...)
Affinity DataIC50: 15.5nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426424(US10526336, Example 43 | ((2R,5R)-5-((3- (difluoro...)
Affinity DataIC50: 15.7nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426468(US10526336, Example 87 | (2-(2H-1,2,3-triazol-2-yl...)
Affinity DataIC50: 15.7nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426433(US10526336, Example 52 | (2-(1H-pyrazol-1-yl)pyrid...)
Affinity DataIC50: 15.8nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426452(US10526336, Example 71 | US10526336, Example 74 | ...)
Affinity DataIC50: 16nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426474(US10526336, Example 91 | (2-(2H-1,2,3-triazol-2-yl...)
Affinity DataIC50: 16.3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426415(US10526336, Example 34 | (2-(2H-1,2,3-triazol-2-yl...)
Affinity DataIC50: 16.3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426445(US10526336, Example 64 | (2-(2,2- difluoroethoxy)p...)
Affinity DataIC50: 17.4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426419(US10526336, Example 38 | (2-(2H-1,2,3-triazol-2-yl...)
Affinity DataIC50: 17.6nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426478(US10526336, Example 95 | (2-(2H-1,2,3-triazol-2-yl...)
Affinity DataIC50: 17.8nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426441(US10526336, Example 60 | (2-(2H-tetrazol-2- yl)phe...)
Affinity DataIC50: 19nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426472(US10526336, Example 89 | (2-(2H-1,2,3-triazol-2-yl...)
Affinity DataIC50: 19.2nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426439(US10526336, Example 58 | (2-(2H-1,2,3-triazol-2-yl...)
Affinity DataIC50: 20.4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426467(US10526336, Example 86 | (2-(2H-1,2,3-triazol-2-yl...)
Affinity DataIC50: 20.5nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426456(US10526336, Example 75 | ((2R,5R)-2-methyl-5-(pyra...)
Affinity DataIC50: 20.6nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426417(US10526336, Example 36 | (2-(2H-1,2,3-triazol-2-yl...)
Affinity DataIC50: 21nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426434(US10526336, Example 53 | ((2R,5R)-5-((3- (difluoro...)
Affinity DataIC50: 21.3nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426387(US10526336, Example 6 | US10526336, Example 11 | (...)
Affinity DataIC50: 22.2nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426488(US10526336, Example 103 | (2-(2H-1,2,3-triazol-2-y...)
Affinity DataIC50: 23.5nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426412(US10526336, Example 31 | ((2R,5R)-5-((3-chloroimid...)
Affinity DataIC50: 23.7nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426446(US10526336, Example 65 | (2-(1H-pyrazol-1- yl)pyri...)
Affinity DataIC50: 24nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426435(US10526336, Example 54 | ((2R,5R)-5-((3-(difluorom...)
Affinity DataIC50: 24.1nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426477(US10526336, Example 94 | (2-ethoxyphenyl)((2R,5R)-...)
Affinity DataIC50: 24.4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426429(US10526336, Example 48 | methyl 2-((2R,5R)-5-((3- ...)
Affinity DataIC50: 24.9nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426431(US10526336, Example 50 | ((2R,5R)-5-((3- (difluoro...)
Affinity DataIC50: 26.5nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426450(US10526336, Example 69 | (2-(2H-1,2,3-triazol-2-yl...)
Affinity DataIC50: 26.8nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426388(US10526336, Example 7 | (2-(2H-1,2,3-triazol-2-yl)...)
Affinity DataIC50: 27.4nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426489(US10526336, Example 104 | (2-(2H-1,2,3-triazol-2-y...)
Affinity DataIC50: 27.6nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

TargetOrexin receptor type 2(Human)
Merck, Sharp & Dohme

US Patent
LigandPNGBDBM426457(US10526336, Example 76 | (2-(2H-tetrazol-2-yl)phen...)
Affinity DataIC50: 27.8nMAssay Description:In a typical experiment the OX1 and OX2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with th...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/25/2020
Entry Details
US Patent

Displayed 1 to 50 (of 212 total ) | Next | Last >>
Jump to: